Buy Like Buffett
Watchlist

Flagship explainer

How ADMA BIOLOGICS, INC. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$510M · 100%Cost of revenue$217M · 43%Gross profit$293M · 57%Operating income$191M · 38%Income before tax$183M · 36%Income tax$35.7M · 7%Net income$147M · 29%As of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$510M100%
  • 10-K · FY 2025Filing detailsAccession 0001140361-26-006815 · filed Feb 25, 2026
Cost of revenue$217M43%
  • 10-K · FY 2025Filing detailsAccession 0001140361-26-006815 · filed Feb 25, 2026
$293M57%
  • 10-K · FY 2025Filing detailsAccession 0001140361-26-006815 · filed Feb 25, 2026
$191M38%
  • 10-K · FY 2025Filing detailsAccession 0001140361-26-006815 · filed Feb 25, 2026
Income before tax$183M36%
  • 10-K · FY 2025Filing detailsAccession 0001140361-26-006815 · filed Feb 25, 2026
Income tax$35.7M7%
  • 10-K · FY 2025Filing detailsAccession 0001140361-26-006815 · filed Feb 25, 2026
$147M29%
  • 10-K · FY 2025Filing detailsAccession 0001140361-26-006815 · filed Feb 25, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001140361-26-006815 · filed Feb 25, 2026
· event Dec 31, 2025 · retrieved Oct 16, 2026 · annual-row source set
Embed this chart

View the full ADMA BIOLOGICS, INC. analysis at Buy Like Buffett